Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
Medtronic Posts Prelim PRODIGY Outcome on Opioid Overdose
by Zacks Equity Research
The favorable PRODIGY study result by Medtronic (MDT) is undoubtedly a timely, strategic finding.
Align Technology Unveils iTero Element 5D Imaging System
by Zacks Equity Research
Align Technology (ALGN) continues to expand work flow options of iTero scanners.
Here's Why You Must Buy Cardiovascular Systems' (CSII) Stock
by Zacks Equity Research
Cardiovascular Systems (CSII) has been firing on all cylinders of late to expand its geographical presence. The company is progressing well with its objective to introduce OAS globally.
Boston Scientific Benefits From New Buyouts & Product Launch
by Zacks Equity Research
Boston Scientific's (BSX) closure of Millipede acquisition and its buyout agreement with BTG plc are major developments for the company.
Edwards Lifesciences to Buy CASMED to Boost Critical Care Arm
by Zacks Equity Research
The CASMED buyout is expected to strengthen Edwards Lifesciences' (EW) position in smart monitoring technologies and boost top-line contributions from the Critical Care arm.
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.
Amedisys (AMED) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Investment Tips to Help You Achieve Your 2019 Goals
by Chandrima Sanyal
Here are a few ways to invest your money that will help you improve your financial health and mitigate the impacts of any potential adversity.
Amedisys (AMED) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amedisys (AMED) closed the most recent trading day at $129.41, moving +1.47% from the previous trading session.
Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.
ADUS vs. AMED: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ADUS vs. AMED: Which Stock Is the Better Value Option?
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMED) Outperforming Other Medical Stocks This Year?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
Thermo Fisher (TMO) Down on Business Divestment Declaration
by Zacks Equity Research
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix
Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)
by Zacks Equity Research
Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.
Bet on DuPont Analysis: Play 5 Quality Stocks
by Sanghamitra Saha
Bet on five top-ranked stocks with higher ROE derived the DuPont way.
Quest Diagnostics' Core Diagnostics Strong Amid Several Woes
by Zacks Equity Research
Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.
Amedisys (AMED) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amedisys (AMED) closed at $127 in the latest trading session, marking a +0.09% move from the prior day.
Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?
by Zacks Equity Research
Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.